Observation of Long-term Effects on Endometrium and Uterine Fibroids in Women With Ulipristal Acetate Therapy
Long-term Observation of Symptomatic Women With Uterine Fibroids Who Have Been Treated With Ulipristal Acetate: Findings on Symptomatology, Morphological Structure, Endometrial Patterns
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: pasquale de franciscis, md phd
- Phone Number: 0039 0815665606
- Email: pasquale.defranciscis@unicampania.it
Study Contact Backup
- Name: Antonio Schiattarella, MD
- Phone Number: 0039 3921653275
- Email: antonio.schiattarella@unicampania.it
Study Locations
-
-
-
Naples, Italy
- Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli"
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- number of myomas from 1 to 4
- heavy menstrual bleeding
- conservative treatment request
Exclusion Criteria:
- concurrent endometrial pathology
- post-menopausal status
- hepatic pathology
- endocrine or metabolic disorders
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ulipristal acetate based therapy
Fertile women under ulipristal acetate treatment
|
Evaluation of endometrial thickness; myoma size and volume
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Dysmenhorrea (VAS score)
Time Frame: 12 months
|
12 months
|
|
Endometrial thickess (mm)
Time Frame: 12 months
|
12 months
|
|
Myoma's diameter (mm)
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Live birth rate (LBR)
Time Frame: 12 months
|
Live birth rate if women conceived spontaneously or through ARTs after treatment
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Gaetano Riemma, MD, University of Campania "Luigi Vanvitelli"
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Pain
- Neurologic Manifestations
- Uterine Diseases
- Connective Tissue Diseases
- Neoplasms, Connective Tissue
- Menstruation Disturbances
- Pelvic Pain
- Neoplasms, Muscle Tissue
- Hemorrhage
- Hyperplasia
- Endometrial Hyperplasia
- Dysmenorrhea
- Metrorrhagia
- Leiomyoma
- Myofibroma
- Uterine Hemorrhage
Other Study ID Numbers
Other Study ID Numbers
- N.595
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.